Twyman RE - Search Results

1

Identification of clinically relevant biomarkers of epileptogenesis - a strategic roadmap.

Simonato M, Agoston DV, Brooks-Kayal A, Dulla C, Fureman B, Henshall DC, Pitkänen A, Theodore WH, Twyman RE, Kobeissy FH, Wang KK, Whittemore V, Wilcox KS. Simonato M, et al. Among authors: twyman re. Nat Rev Neurol. 2021 Apr;17(4):231-242. doi: 10.1038/s41582-021-00461-4. Epub 2021 Feb 16. Nat Rev Neurol. 2021. PMID: 33594276 Review.

2

Antiepileptogenesis and disease modification: Progress, challenges, and the path forward-Report of the Preclinical Working Group of the 2018 NINDS-sponsored antiepileptogenesis and disease modification workshop.

Galanopoulou AS, Löscher W, Lubbers L, O'Brien TJ, Staley K, Vezzani A, D'Ambrosio R, White HS, Sontheimer H, Wolf JA, Twyman R, Whittemore V, Wilcox KS, Klein B. Galanopoulou AS, et al. Epilepsia Open. 2021 Jun;6(2):276-296. doi: 10.1002/epi4.12490. Epub 2021 May 6. Epilepsia Open. 2021. PMID: 34033232 Free PMC article.

3

New avenues for anti-epileptic drug discovery and development.

Löscher W, Klitgaard H, Twyman RE, Schmidt D. Löscher W, et al. Among authors: twyman re. Nat Rev Drug Discov. 2013 Oct;12(10):757-76. doi: 10.1038/nrd4126. Epub 2013 Sep 20. Nat Rev Drug Discov. 2013. PMID: 24052047 Review.

4

Autoantibodies to glutamate receptor subunit GluR2 in nonfamilial olivopontocerebellar degeneration.

Gahring LC, Rogers SW, Twyman RE. Gahring LC, et al. Among authors: twyman re. Neurology. 1997 Feb;48(2):494-500. doi: 10.1212/wnl.48.2.494. Neurology. 1997. PMID: 9040745

5

Antiepileptogenesis and disease modification: Clinical and regulatory issues.

French JA, Bebin M, Dichter MA, Engel J Jr, Hartman AL, Jóźwiak S, Klein P, McNamara J Sr, Twyman R, Vespa P. French JA, et al. Epilepsia Open. 2021 Sep;6(3):483-492. doi: 10.1002/epi4.12526. Epub 2021 Jul 29. Epilepsia Open. 2021. PMID: 34270884 Free PMC article.

6

Antibodies to glutamate receptors: a role in excitatory dysregulation of the central nervous system?

Twyman RE, Rogers SW, Gahring LC, Carlson NG, Donevan SD. Twyman RE, et al. Adv Neurol. 1999;79:535-41. Adv Neurol. 1999. PMID: 10514841 Review. No abstract available.

7

Potent and selective pharmacodynamic synergy between the metabotropic glutamate receptor subtype 2-positive allosteric modulator JNJ-46356479 and levetiracetam in the mouse 6-Hz (44-mA) model.

Metcalf CS, Klein BD, Smith MD, Ceusters M, Lavreysen H, Pype S, Van Osselaer N, Twyman R, White HS. Metcalf CS, et al. Epilepsia. 2018 Mar;59(3):724-735. doi: 10.1111/epi.14005. Epub 2018 Jan 23. Epilepsia. 2018. PMID: 29360159

8

Efficacy of mGlu₂ -positive allosteric modulators alone and in combination with levetiracetam in the mouse 6 Hz model of psychomotor seizures.

Metcalf CS, Klein BD, Smith MD, Pruess T, Ceusters M, Lavreysen H, Pype S, Van Osselaer N, Twyman R, White HS. Metcalf CS, et al. Epilepsia. 2017 Mar;58(3):484-493. doi: 10.1111/epi.13659. Epub 2017 Feb 6. Epilepsia. 2017. PMID: 28166368

9

Correlation analysis between anticonvulsant ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels.

Bialer M, Twyman RE, White HS. Bialer M, et al. Among authors: twyman re. Epilepsy Behav. 2004 Dec;5(6):866-72. doi: 10.1016/j.yebeh.2004.08.021. Epilepsy Behav. 2004. PMID: 15582834

10

The dihydropyridine nitrendipine reduces N-methyl-D-aspartate (NMDA)-evoked currents of rodent cortical neurons through a direct interaction with the NMDA receptor-associated ion channel.

Skeen GA, White HS, Twyman RE. Skeen GA, et al. Among authors: twyman re. J Pharmacol Exp Ther. 1994 Oct;271(1):30-8. J Pharmacol Exp Ther. 1994. PMID: 7965728

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

45 results

Search Page